B2M and neoplasm: The presence of simultaneous LOH and frameshift B2M mutations in Pat208, along with concurrent loss of B2M and HLA Class I protein expression, suggests that B2M aberrations could contribute to tumor evasion of CD8+ T-cell responses and disease progression.